Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 2/20 | 0.69 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.67 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.67 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
| ▸ | NOS2 | P35228 | 2/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | APEX1 | P27695 | 1/20 | 0.50 |
| ▸ | ARG2 | P78540 | 4/20 | 0.47 |
| ▸ | ARG1 | P05089 | 3/20 | 0.47 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.45 |
| ▸ | GRM8 | O00222 | 1/20 | 0.45 |
| ▸ | GRM6 | O15303 | 1/20 | 0.45 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.45 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.45 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.45 |
| ▸ | GRM5 | P41594 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ornithine Aketoglutarate SCHEMBL1696575 | 1.00 | GSR (0.69) | GSRPTGS1SLC7A11CPB2CYP1A2 | |
| Lysine SCHEMBL1535094 | 0.94 | GSR (0.80) | GSRPTGS1SLC7A11CPB2CYP1A2 | |
| Lysine SCHEMBL4272062 | 0.94 | GSR (0.80) | GSRPTGS1SLC7A11CPB2CYP1A2 | |
| Lysine SCHEMBL23648486 | 0.94 | GSR (0.80) | GSRPTGS1SLC7A11CPB2CYP1A2 | |
| Lysine SCHEMBL29037480 | 0.94 | GSR (0.80) | GSRPTGS1SLC7A11CPB2CYP1A2 | |
| Lysine SCHEMBL23648487 | 0.94 | GSR (0.80) | GSRPTGS1SLC7A11CPB2CYP1A2 | |
| Lysine SCHEMBL17835868 | 0.94 | GSR (0.80) | GSRPTGS1SLC7A11CPB2CYP1A2 | |
| D-Ornithine SCHEMBL43724 | 0.89 | — | — | |
| Ornithine Aketoglutarate SCHEMBL1326163 | 0.89 | GSR (0.86) | GSRCPB2CYP1A2CYP2C19NOS2 | |
| Ornithine SCHEMBL624782 | 0.89 | GSR (0.86) | GSRCPB2CYP1A2CYP2C19NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11351268-B2 | FGF21 C-terminal peptide optimization | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2022-06-07 | — | — | US | disclosed |
| US-20200360530-A1 | FGF21 C-TERMINAL PEPTIDE OPTIMIZATION | UNIV INDIANA RES & TECH CORP (US) | 2020-11-19 | — | — | US | disclosed |
| EP-2970511-B1 | INSULIN-INCRETIN CONJUGATES | UNIV INDIANA RES & TECH CORP (US) | 2020-09-30 | — | — | EP | disclosed |
| US-10696726-B2 | Insulin-incretin conjugates | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2020-06-30 | — | — | US | disclosed |
| CN-105324397-B | Insulin-incretin conjugates | 印第安纳大学研究及科技有限公司 | 2020-01-14 | — | — | CN | disclosed |
| EP-3395358-B1 | INSULIN ANALOG DIMERS | UNIV INDIANA RES & TECH CORP (US) | 2019-11-06 | — | — | EP | disclosed |
| US-20190142963-A1 | FGF21 C-TERMINAL PEPTIDE OPTIMIZATION | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2019-05-16 | — | — | US | disclosed |
| US-10233225-B2 | Single chain insulin agonists exhibiting high activity at the insulin receptor | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2019-03-19 | — | — | US | disclosed |
| EP-3442997-A2 | FGF21 C-TERMINAL PEPTIDE OPTIMIZATION | Indiana University Research & Technology Corporation (US) | 2019-02-20 | — | — | EP | disclosed |
| EP-2900255-B1 | INSULIN ANALOG DIMERS | UNIV INDIANA RES & TECH CORP (US) | 2019-01-30 | — | — | EP | disclosed |
| US-20150274802-A1 | INSULIN ANALOG DIMERS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2015-10-01 | — | — | US | disclosed |
| EP-2900255-A2 | INSULIN ANALOG DIMERS | Indiana University Research and Technology Corporation (US) | 2015-08-05 | — | — | EP | disclosed |
| US-20150148520-A1 | SINGLE-CHAIN INSULIN AGONISTS EXHIBITING HIGH ACTIVITY AT THE INSULIN RECEPTOR | UNIV INDIANA RES & TECH CORP (US) | 2015-05-28 | — | — | US | disclosed |
| US-8940860-B2 | Single-chain insulin agonists exhibiting high activity at the insulin receptor | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2015-01-27 | — | — | US | disclosed |
| WO-2014158900-A1 | INSULIN-INCRETIN CONJUGATES | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2014-10-02 | — | — | WO | disclosed |
| US-20130203665-A1 | SINGLE-CHAIN INSULIN AGONISTS EXHIBITING HIGH ACTIVITY AT THE INSULIN RECEPTOR | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2013-08-08 | — | — | US | disclosed |
| EP-2582719-A2 | SINGLE CHAIN INSULIN AGONISTS EXHIBITING HIGH ACTIVITY AT THE INSULIN RECEPTOR | Indiana University Research And Technology Corporation (US) | 2013-04-24 | — | — | EP | disclosed |
| WO-2011159895-A2 | SINGLE CHAIN INSULIN AGONISTS EXHIBITING HIGH ACTIVITY AT THE INSULIN RECEPTOR | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2011-12-22 | — | — | WO | disclosed |
| EP-0546108-A4 | PRO-DRUGS FOR CCK ANTAGONISTS | — | 1993-09-22 | — | — | EP | disclosed |
| EP-0546108-A1 | PRO-DRUGS FOR CCK ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1993-06-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150148520-A1 | SINGLE-CHAIN INSULIN AGONISTS EXHIBITING HIGH ACTIVITY AT THE INSULIN RECEPTOR | IGF1R, GPR119, IRS1 | GSR 4108/4885PTGS1 2854/4885SLC7A11 3557/4885 |
| US-11351268-B2 | FGF21 C-terminal peptide optimization | FGF23, FGFR1, FGFR3 | GSR 2006/4885PTGS1 4814/4885SLC7A11 1369/4885 |
| US-20150274802-A1 | INSULIN ANALOG DIMERS | INSR, IAPP, GPR119 | GSR 4013/4885PTGS1 4073/4885SLC7A11 3759/4885 |
| US-20190142963-A1 | FGF21 C-TERMINAL PEPTIDE OPTIMIZATION | FGF23, FGFR1, FGFR3 | GSR 2006/4885PTGS1 4814/4885SLC7A11 1369/4885 |
| US-10696726-B2 | Insulin-incretin conjugates | GLP1R, IAPP, GIPR | GSR 2074/4885PTGS1 4694/4885SLC7A11 1674/4885 |
| US-10233225-B2 | Single chain insulin agonists exhibiting high activity at the insulin receptor | IGF1R, GPR119, IRS1 | GSR 4183/4885PTGS1 2931/4885SLC7A11 3717/4885 |
| US-20130203665-A1 | SINGLE-CHAIN INSULIN AGONISTS EXHIBITING HIGH ACTIVITY AT THE INSULIN RECEPTOR | IGF1R, GPR119, IRS1 | GSR 4108/4885PTGS1 2854/4885SLC7A11 3557/4885 |
| US-20200360530-A1 | FGF21 C-TERMINAL PEPTIDE OPTIMIZATION | FGF23, FGFR1, FGFR3 | GSR 2006/4885PTGS1 4814/4885SLC7A11 1369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.